市场调查报告书
商品编码
1273578
到 2028 年切向流过滤市场预测 - 按产品、膜材料(尼龙、聚偏二氟乙烯等)、技术、应用、最终用户和地区分列的全球分析Tangential Flow Filtration Market Forecasts to 2028 - Global Analysis By Product, Membrane Material (Nylon and Polyvinylidene Difluoride and Other Materials), Technique, Application, End User and By Geography |
根据Stratistics MRC,2022年全球切向流过滤市场规模将达到15亿美元,预计2028年将达到35亿美元,预测期内增长15.2%。以復合年增长率增长
切向流过滤 (TFF) 是纯化和分离生物分子的有效方法。 切向流过滤,也称为错流过滤,可用于细胞收穫的上游过程和生物製造中使用的下游过程。 从 10 mL 到数千升的样品溶液都可以浓缩和脱盐。 通过大量分离收穫的细胞悬浮液、小生物分子、发酵液、细胞裂解物等获得。
根据塔夫茨药物开发研究中心 2021 年的一份报告,最大的上市生物技术公司的全球研发支出增长了 13.7%每年从 2001 年的 48 亿美元增加到 2020 年的 550 亿美元
典型的切向流过滤工艺包括反渗透和纳滤。 浓缩和渗滤技术使用切向流过滤。 它通过去除液体同时保留溶质分子来增加溶液的浓度。 在渗滤中,小颗粒与大颗粒分离,剩余的盐分用另一种缓衝液洗掉,最后留下小颗粒,总浓度不变。 该方法也可用于通过用水洗去残留的盐来降低溶液的浓度。 因此,切向流过滤利用率的提高正在推动预测期内切向流过滤市场的增长。
建造或新建製造设备需要大量的资金投入,小企业可能难以有备选方案应对。 此外,离心、直流过滤和预涂过滤等尖端技术的出现预计将阻碍全球切向流过滤市场的扩张。 此外,许多製药公司不断将生产外包,以有效利用海外的技术、经验和能力。 结果,成品价格将上涨,这可能会阻碍市场扩张。
切向流过滤 (TFF) 是一种快速有效的生物分子分离和纯化技术。 它在许多科学领域都很有用,例如免疫学、蛋白质化学、分子生物学(DNA/RNA/寡核甘酸)、生物化学和微生物学。 多年来,TFF 一直用于浓缩和脱盐蛋白质和□,从细胞培养基中回收和纯化抗体和重组蛋白质,以及分离稀释的蛋白质混合物。 此外,随着治疗方式转向重症监护,转基因蛋白质的治疗应用正在扩大。 生物製药行业正趋向于将重组蛋白商业化,这预计将推动切向流过滤市场的增长。
预计在预测期内,製药行业普遍存在严格的政府法规,这将为全球切向流过滤市场带来挑战。 此外,市场上既定且强大的竞争对手的存在使新进入者难以为其产品和新技术做广告。 此外,该市场的主要竞争对手提供范围广泛的过滤产品,并享有较高的客户品牌忠诚度,这使得新进入者更难在该行业立足。
COVID-19 大流行增加了全球经济和社会成本,促使各国政府加紧疫苗开发和製造。 切向流过滤产品越来越多地用于 COVID-19 研究。 各种过滤技术和材料用于支持下游过程,例如用于疫苗开发的过滤和纯化。 此外,一些生物製药公司已采取多种策略来改进疫苗开发并遏制大流行。 COVID-19 疫情也为过滤器製造商扩大生产设施创造了机会。 这些过滤产品用于製造疫苗和其他医药产品,因此疫苗的大规模生产对切向流过滤产品的需求产生了积极影响。
由于过滤系统在许多行业(尤其是製药行业)中的使用,据估计膜过滤器将获得有利可图的增长。 这一领域的扩大是由于容易获得各种类型的过滤器,如 PCTE、PVDF、PTFE 和 PES。 此外,相关工艺中各种膜过滤面积和孔径的可用性也在推动该领域的扩展。
由于在细胞分离过程中越来越多地使用微滤技术,预计微滤部分在预测期内将以最快的复合年增长率增长。 另一方面,微滤膜用于应对微生物去除、蛋白质分离和膜处理等各种挑战,推动了该细分市场的扩张。 此外,由于孔径在0.1到10m之间变化,因此可以抑制结垢和分离悬浮颗粒。 这些因素预计将在预测期内促进该部门的增长。
亚太地区受到生物製剂和製药需求不断增长、国内外公司大量投资以及 CMO 在中国、日本和韩国等新兴市场扩张的推动,推动了该行业的增长。 , 预计在预测期内将占据最大的市场份额。 此外,治疗的现代化、医疗保健基础设施的发展以及对低成本药品需求的关注预计将推动亚太地区 TFF 市场的增长。
预计北美在预测期内的复合年增长率最高。 这是由于为满足生物治疗需求而增加的生物工艺活动、慢性病和遗传异常的频率增加、治疗安全知识的增加以及医疗保健环境的改善正在支持该地区的增长。 此外,政府的支持也促进了发展。
2021 年 12 月,唐纳森公司(美国)将收购 Solaris S.p.A.(意大利),该公司设计和製造生物工艺设备,例如用于生物技术和其他生命科学市场的切向流过滤系统。 此次收购扩大了公司在製药行业的投资组合。
2020 年 3 月,丹纳赫从通用电气公司手中收购了生物製药业务。 该部门将被称为 Cytiva,并将成为丹纳赫生命科学部门下运营的一家独立公司。
According to Stratistics MRC, the Global Tangential Flow Filtration Market is accounted for $1.5 billion in 2022 and is expected to reach $3.5 billion by 2028 growing at a CAGR of 15.2% during the forecast period. Tangential flow filtration (TFF) is an effective approach for biomolecule purification and separation. Tangential flow filtration, also known as cross-flow filtration, is useful in both the upstream processing of cell harvesting and the downstream processing approach utilised in bio-manufacturing. It concentrates and desalts sample solutions in amounts ranging from 10 mL to thousands of litres. It is obtained through massive fractionation of harvest cell suspensions, tiny biomolecules, fermentation broths, and cell lysates.
According to a US-based independent, academic, non-profit research center, Tufts Center for the Study of Drug Development's 2021 report, the global R&D spending by the largest publicly-traded biotech companies grew 13.7% annually, from $4.8 billion in 2001 to $55.0 billion in 2020
Typical tangential flow filtering processes include reverse osmosis and nanofiltration. In concentration and diafiltration techniques, tangential flow filtration is used. It increases a solution's concentration by removing liquids while maintaining the solute molecules. In diafiltration, tiny and giant particles separate, leaving the tinier particles behind without changing the total concentration at the end by washing out the rest of the salt with another buffer. This approach can also be used to reduce the concentration of a solution by washing away the remaining salts with water. Tangential flow filtration's increasing use is thus fuelling the growth of the Tangential Flow Filtration Market during the forecast period.
High capital expenditure is necessary to construct and establish new manufacturing facilities, which may be difficult or easy to option out by small-scale businesses. Furthermore, the presence of cutting-edge technologies such as centrifugation, direct flow filtration, and pre-coat filtration is expected to hamper the worldwide tangential flow filtration market's expansion. Furthermore, numerous pharmaceutical corporations are constantly outsourcing manufacturing in order to effectively utilise foreign technology, experience, and capacity. As a result, the prices of finished items may rise, stifling market expansion.
Tangential flow filtration (TFF) is an immediate and effective technique for biomolecule separation and purification. It is useful in many scientific domains, including immunology, protein chemistry, molecular biology (DNA/RNA/oligonucleotides), biochemistry, and microbiology. TFF has been used to concentrate and desalt proteins and peptides, recover and purify antibodies or recombinant proteins from cell culture medium, and fractionate dilute protein mixtures over the years. Recombinant proteins have received substantial momentum for therapeutic uses as the treatment pattern has shifted towards focused therapy. The biopharmaceutical industry's tendency of commercialising recombinant proteins is projected to drive the growth of the tangential flow filtration market.
The prevalence of rigorous government laws and regulations in the pharmaceutical business is expected to offer a challenge to the worldwide tangential flow filtration market during the forecast period. Furthermore, the market's presence of well-established and prominent competitors makes it difficult for new entrants to advertise their product offers and novel technology. Furthermore, important competitors in this market offer a wide selection of filtration products and have high levels of brand loyalty from customers, making it even more difficult for new entrants to establish a foothold in the industry.
The COVID-19 pandemic increased the global economic and social cost, prompting governments to increase vaccine development and manufacturing. Tangential flow filtration products are increasingly being used for COVID-19 research. To support downstream processes such as filtration and purification for vaccine development, various filtration techniques and materials are used. Moreover, some biopharmaceutical companies have incorporated several strategies to improve vaccine development and contain the pandemic. The COVID-19 epidemic has also created chances for filter manufacturers to expand their manufacturing facilities. As these filtering goods are utilised in the production of vaccines and other medicinal medications, the mass production of vaccines has favourably influenced the demand for tangential flow filtration products.
The membrane filters segment is estimated to have a lucrative growth, due to the use of filtering systems in numerous industries, particularly the pharmaceutical industry, is the primary driver of this segment's growth. The segment's expansion is being driven by the ease of access to various types of filters such as PCTE, PVDF, PTFE, and PES. Furthermore, the availability of diverse membrane filtration areas and pore sizes for relevant processes encourages segment expansion.
The microfiltration segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the increased use of microfiltration techniques during cell separation procedures. Microfiltration membranes, on the other hand, are used to handle a variety of challenges such as microbial removal, protein separation, and membrane treatment, which is driving the segment's expansion. Furthermore, these membranes are available in a variety of pore diameters ranging from 0.1 to 10 m, which aids in limiting fouling and fractionating suspended particles. These factors will contribute to the segment's growth during the predicted period.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing demand for biologics and medicines, considerable investments from domestic and international firms, and the expansion of CMOs in emerging markets such as China, Japan, and South Korea are all driving to the industry's growth. Furthermore, the focus on treatment modernization, healthcare infrastructure development, and need for low-cost pharmaceuticals would drive the growth of the TFF market in APAC.
North America is projected to have the highest CAGR over the forecast period, owing to the increased bioprocessing activities to meet bio-therapeutic demand, increased frequency of chronic diseases and genetic abnormalities, expanding knowledge about treatment safety, and enhanced healthcare settings have all supported regional growth. Furthermore, the presence of a supportive government promotes development.
Some of the key players profiled in the Tangential Flow Filtration Market include: Andritz, Synder Filtration, INC., Merk KGAA, SPF Technologies, LLC, Parker Hannifin Corporation, Danaher Corporation, Sysbiotech Gmbh, Solaris Biotechnology SRL, Alfa Laval Corporate AB, Sartorius AG, Sterlitech Corporation, Koch Separation Solutions, Cole-Parmer Instrument Company, LLC, Repligen Corporation and Meissner Filtration Products, INC.
In December 2021, Donaldson Company (US) acquired Solaris (Italy), a company that designs and manufactures bioprocessing equipment, including tangential flow filtration systems for use in biotechnology, and other life sciences markets. This acquisition will expand the company's portfolio in the pharmaceutical industry.
In March 2020, Danaher acquired the biopharma business from General Electric Company. This division will be called Cytiva and will be a standalone company operating under the Danaher Life Sciences segment.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.